ReviewTherapeutic advances in psychopharmacology2026
Modafinil-associated psychosis: a systematic review of case characteristics and management strategies.
Review in Therapeutic advances in psychopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Modafinil is a wakefulness-promoting agent widely used for narcolepsy and other sleep disorders. Although considered relatively safe, psychotic episodes associated with its use have been reported. However, no systematic review has focused on modafinil-associated psychosis. Objectives: To synthesize and describe the clinical characteristics, diagnostic backgrounds, and treatment outcomes of modafinil-associated psychosis through a systematic review of case reports and series. Design: Systematic review of published case reports and case series. Data sources and methods: A systematic literature search was conducted using PubMed and Web of Science. Case reports and series in English describing psychosis related to modafinil or armodafinil use were included. Age, sex, dose, diagnosis, symptoms, treatment, and outcomes were extracted and descriptively analyzed. Results: Twenty-four patients (13 men and 11 women, mean age 37.4 years) from 21 articles were included. The most common symptoms were hallucinations (66.7%) and delusions (58.3%). Median modafinil dose was 250 mg/day; however, some patients received excessive doses. The diagnoses included narcolepsy (33.3%), schizophrenia (20.8%), and depression (20.8%). Eighteen patients (75.0%) were treated with antipsychotics, and 16 (66.7%) discontinued modafinil. Most patients (70.8%) showed marked improvement. Conclusion: Modafinil-associated psychosis can develop across wide diagnostic and age ranges, and sometimes even at therapeutic doses. Although the potential risk factors remain unclear, caution should be exercised regarding the drug's use at high doses, in patients with comorbid psychiatric conditions, and in cases of off-label usage for cognitive enhancement. Long-term follow-up is necessary to monitor outcomes and transition to schizophrenia. Further research is needed to identify the predictive factors and elucidate the underlying neurobiological mechanisms. Trial registration: Not registered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.